NASDAQ:AXGN

AxoGen Competitors

$20.06
0.00 (0.00 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$19.76
Now: $20.06
$20.12
50-Day Range
$18.95
MA: $20.53
$22.60
52-Week Range
$7.16
Now: $20.06
$22.89
Volume110,493 shs
Average Volume243,385 shs
Market Capitalization$817.89 million
P/E RatioN/A
Dividend YieldN/A
Beta0.71

Competitors

AxoGen (NASDAQ:AXGN) Vs. INMD, OM, BLFS, NTUS, TMDX, and VRAY

Should you be buying AXGN stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to AxoGen, including InMode (INMD), Outset Medical (OM), BioLife Solutions (BLFS), Natus Medical (NTUS), TransMedics Group (TMDX), and ViewRay (VRAY).

InMode (NASDAQ:INMD) and AxoGen (NASDAQ:AXGN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk.

Insider and Institutional Ownership

35.7% of InMode shares are held by institutional investors. Comparatively, 78.4% of AxoGen shares are held by institutional investors. 6.9% of AxoGen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares InMode and AxoGen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InMode32.57%28.56%24.14%
AxoGen-22.98%-19.83%-14.88%

Earnings and Valuation

This table compares InMode and AxoGen's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InMode$156.36 million16.50$61.15 million$1.6050.43
AxoGen$106.71 million7.66$-29,140,000.00($0.68)-29.50

InMode has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations and price targets for InMode and AxoGen, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
InMode00403.00
AxoGen02302.60

InMode currently has a consensus target price of $71.50, suggesting a potential downside of 11.39%. AxoGen has a consensus target price of $23.75, suggesting a potential upside of 18.39%. Given AxoGen's higher probable upside, analysts plainly believe AxoGen is more favorable than InMode.

Volatility & Risk

InMode has a beta of 1.95, indicating that its stock price is 95% more volatile than the S&P 500. Comparatively, AxoGen has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500.

Summary

InMode beats AxoGen on 11 of the 14 factors compared between the two stocks.

AxoGen (NASDAQ:AXGN) and Outset Medical (NASDAQ:OM) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Insider and Institutional Ownership

78.4% of AxoGen shares are owned by institutional investors. Comparatively, 84.6% of Outset Medical shares are owned by institutional investors. 6.9% of AxoGen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares AxoGen and Outset Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AxoGen-22.98%-19.83%-14.88%
Outset MedicalN/AN/AN/A

Earnings & Valuation

This table compares AxoGen and Outset Medical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AxoGen$106.71 million7.66$-29,140,000.00($0.68)-29.50
Outset MedicalN/AN/AN/AN/AN/A

Outset Medical has lower revenue, but higher earnings than AxoGen.

Analyst Recommendations

This is a summary of current ratings and target prices for AxoGen and Outset Medical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AxoGen02302.60
Outset Medical03402.57

AxoGen presently has a consensus price target of $23.75, suggesting a potential upside of 18.39%. Outset Medical has a consensus price target of $56.50, suggesting a potential downside of 3.14%. Given AxoGen's stronger consensus rating and higher possible upside, equities research analysts clearly believe AxoGen is more favorable than Outset Medical.

Summary

Outset Medical beats AxoGen on 5 of the 9 factors compared between the two stocks.

AxoGen (NASDAQ:AXGN) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Insider and Institutional Ownership

78.4% of AxoGen shares are owned by institutional investors. Comparatively, 67.7% of BioLife Solutions shares are owned by institutional investors. 6.9% of AxoGen shares are owned by insiders. Comparatively, 22.3% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares AxoGen and BioLife Solutions' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AxoGen-22.98%-19.83%-14.88%
BioLife Solutions12.67%0.53%0.43%

Earnings & Valuation

This table compares AxoGen and BioLife Solutions' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AxoGen$106.71 million7.66$-29,140,000.00($0.68)-29.50
BioLife Solutions$27.37 million43.93$-1,660,000.00$0.08450.00

BioLife Solutions has lower revenue, but higher earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and target prices for AxoGen and BioLife Solutions, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AxoGen02302.60
BioLife Solutions01902.90

AxoGen presently has a consensus price target of $23.75, suggesting a potential upside of 18.39%. BioLife Solutions has a consensus price target of $46.6667, suggesting a potential upside of 29.63%. Given BioLife Solutions' stronger consensus rating and higher possible upside, analysts clearly believe BioLife Solutions is more favorable than AxoGen.

Risk & Volatility

AxoGen has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.

Summary

BioLife Solutions beats AxoGen on 11 of the 14 factors compared between the two stocks.

AxoGen (NASDAQ:AXGN) and Natus Medical (NASDAQ:NTUS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, profitability, analyst recommendations and risk.

Profitability

This table compares AxoGen and Natus Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AxoGen-22.98%-19.83%-14.88%
Natus Medical-4.33%3.87%2.50%

Insider and Institutional Ownership

78.4% of AxoGen shares are owned by institutional investors. Comparatively, 89.7% of Natus Medical shares are owned by institutional investors. 6.9% of AxoGen shares are owned by insiders. Comparatively, 1.5% of Natus Medical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares AxoGen and Natus Medical's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AxoGen$106.71 million7.66$-29,140,000.00($0.68)-29.50
Natus Medical$495.52 million1.78$-15,670,000.00$1.2421.03

Natus Medical has higher revenue and earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Natus Medical, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

AxoGen has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Natus Medical has a beta of 0.72, suggesting that its stock price is 28% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for AxoGen and Natus Medical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AxoGen02302.60
Natus Medical01002.00

AxoGen presently has a consensus price target of $23.75, suggesting a potential upside of 18.39%. Given AxoGen's stronger consensus rating and higher possible upside, equities research analysts clearly believe AxoGen is more favorable than Natus Medical.

Summary

Natus Medical beats AxoGen on 8 of the 14 factors compared between the two stocks.

AxoGen (NASDAQ:AXGN) and TransMedics Group (NASDAQ:TMDX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Profitability

This table compares AxoGen and TransMedics Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AxoGen-22.98%-19.83%-14.88%
TransMedics Group-131.35%-38.95%-24.10%

Insider & Institutional Ownership

78.4% of AxoGen shares are owned by institutional investors. Comparatively, 76.7% of TransMedics Group shares are owned by institutional investors. 6.9% of AxoGen shares are owned by company insiders. Comparatively, 13.1% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares AxoGen and TransMedics Group's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AxoGen$106.71 million7.66$-29,140,000.00($0.68)-29.50
TransMedics Group$23.60 million36.83$-33,550,000.00($2.36)-13.46

AxoGen has higher revenue and earnings than TransMedics Group. AxoGen is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

AxoGen has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for AxoGen and TransMedics Group, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AxoGen02302.60
TransMedics Group02302.60

AxoGen presently has a consensus price target of $23.75, suggesting a potential upside of 18.39%. TransMedics Group has a consensus price target of $44.20, suggesting a potential upside of 39.17%. Given TransMedics Group's higher possible upside, analysts clearly believe TransMedics Group is more favorable than AxoGen.

Summary

AxoGen beats TransMedics Group on 7 of the 12 factors compared between the two stocks.

AxoGen (NASDAQ:AXGN) and ViewRay (NASDAQ:VRAY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, profitability, analyst recommendations, risk and valuation.

Profitability

This table compares AxoGen and ViewRay's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AxoGen-22.98%-19.83%-14.88%
ViewRay-166.74%-63.41%-36.34%

Insider & Institutional Ownership

78.4% of AxoGen shares are owned by institutional investors. Comparatively, 83.0% of ViewRay shares are owned by institutional investors. 6.9% of AxoGen shares are owned by company insiders. Comparatively, 15.5% of ViewRay shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares AxoGen and ViewRay's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AxoGen$106.71 million7.66$-29,140,000.00($0.68)-29.50
ViewRay$87.78 million7.86$-120,200,000.00($1.18)-3.64

AxoGen has higher revenue and earnings than ViewRay. AxoGen is trading at a lower price-to-earnings ratio than ViewRay, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

AxoGen has a beta of 0.71, suggesting that its share price is 29% less volatile than the S&P 500. Comparatively, ViewRay has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for AxoGen and ViewRay, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AxoGen02302.60
ViewRay11502.57

AxoGen presently has a consensus price target of $23.75, suggesting a potential upside of 18.39%. ViewRay has a consensus price target of $4.50, suggesting a potential upside of 4.90%. Given AxoGen's stronger consensus rating and higher possible upside, analysts clearly believe AxoGen is more favorable than ViewRay.

Summary

AxoGen beats ViewRay on 9 of the 14 factors compared between the two stocks.


AxoGen Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
InMode logo
INMD
InMode
1.5$80.69flat$2.58 billion$156.36 million58.05News Coverage
Outset Medical logo
OM
Outset Medical
0.9$58.33flat$2.50 billionN/A0.00News Coverage
Gap Up
BioLife Solutions logo
BLFS
BioLife Solutions
2.1$36.00flat$1.20 billion$27.37 million-49.31
NTUS
Natus Medical
1.1$26.08flat$883.43 million$495.52 million-47.42News Coverage
TransMedics Group logo
TMDX
TransMedics Group
1.6$31.76flat$869.27 million$23.60 million-22.69Insider Selling
News Coverage
ViewRay logo
VRAY
ViewRay
1.3$4.29flat$689.84 million$87.78 million-4.82News Coverage
Cutera logo
CUTR
Cutera
1.3$31.40flat$558.39 million$181.71 million-17.35News Coverage
Zynex logo
ZYXI
Zynex
1.8$15.65flat$545.48 million$45.47 million47.42News Coverage
Gap Up
Edap Tms logo
EDAP
Edap Tms
1.3$9.14flat$266.36 million$50.23 million-152.33
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$8.86flat$206.00 million$3.38 million-4.64Unusual Options Activity
Gap Up
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$4.57flat$145.28 millionN/A0.00Gap Up
FONR
FONAR
1.1$18.62flat$122.04 million$85.69 million17.57News Coverage
IRIDEX logo
IRIX
IRIDEX
0.9$7.30flat$113.30 million$43.45 million-13.27
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.54flat$105.66 million$10,000.00-1.38News Coverage
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.21flat$96.47 millionN/A-1.59News Coverage
electroCore logo
ECOR
electroCore
1.4$1.96flat$95.02 million$2.39 million-2.48News Coverage
Gap Down
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.5$17.86flat$41.27 million$1.50 million-1.02
Viveve Medical logo
VIVE
Viveve Medical
0.9$3.25flat$33.61 million$6.57 million-0.01Gap Up
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.40flat$32.60 million$5.51 million-0.11Analyst Upgrade
News Coverage
Gap Down
STRR
Star Equity
0.1$3.30flat$16.24 million$114.18 million-1.05Gap Up
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.